New combo therapy aims to deepen remissions in CLL
NCT ID NCT05971251
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether adding loncastuximab tesirine to the standard drug acalabrutinib is safe and effective for people with chronic lymphocytic leukemia (CLL). About 24 adults with CLL will receive the combination to find the best dose and see if it can make the cancer undetectable in the blood. The goal is to improve disease control, not to cure the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?